246 related articles for article (PubMed ID: 27564568)
1. Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.
Liu C; Yang W; Pei D; Cheng C; Smith C; Landier W; Hageman L; Chen Y; Yang JJ; Crews KR; Kornegay N; Karol SE; Wong FL; Jeha S; Sandlund JT; Ribeiro RC; Rubnitz JE; Metzger ML; Pui CH; Evans WE; Bhatia S; Relling MV
Clin Pharmacol Ther; 2017 Mar; 101(3):373-381. PubMed ID: 27564568
[TBL] [Abstract][Full Text] [Related]
2. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
4. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
5. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity.
Liu C; Janke LJ; Yang JJ; Evans WE; Schuetz JD; Relling MV
Cancer Chemother Pharmacol; 2017 Aug; 80(2):287-293. PubMed ID: 28623449
[TBL] [Abstract][Full Text] [Related]
7. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism.
Jones TS; Yang W; Evans WE; Relling MV
Clin Pharmacol Ther; 2007 May; 81(5):729-34. PubMed ID: 17329987
[TBL] [Abstract][Full Text] [Related]
8. Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers.
Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Martínez-Ingelmo C; Ortega-Ruíz L; Sarmiento-Iglesias C; Herrador C; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):449-455. PubMed ID: 30346660
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Thiopurine S-Methyltransferase Deficient Alleles in Acute Lymphoblastic Leukemia Patients in Mexican Patients.
Jiménez-Morales S; Ramírez-Florencio M; Mejía-Aranguré JM; Núñez-Enríquez JC; Bekker-Mendez C; Torres-Escalante JL; Flores-Lujano J; Jiménez-Hernández E; Del Carmen Rodríguez-Zepeda M; Leal YA; González-Montalvo PM; Pantoja-Guillen F; Peñaloza-Gonzalez JG; Gutiérrez-Juárez EI; Núñez-Villegas NN; Pérez-Saldivar ML; Guerra-Castillo FX; Flores-Villegas LV; Ramos-Cervantes MT; Fragoso JM; García-Escalante MG; Del Carmen Pinto-Escalante D; Ramírez-Bello J; Hidalgo-Miranda A
Arch Med Res; 2016 Nov; 47(8):615-622. PubMed ID: 28476189
[TBL] [Abstract][Full Text] [Related]
10. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
11. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
Karas-Kuzelicki N; Mlinaric-Rascan I
Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
McLeod HL; Krynetski EY; Relling MV; Evans WE
Leukemia; 2000 Apr; 14(4):567-72. PubMed ID: 10764140
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia].
Ma XL; Zhu P; Wu MY; Li ZG; Hu YM
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):929-33. PubMed ID: 14723818
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
15. [Effect of genetic polymorphism of TPMT and NUDT15 on the tolerance of 6-mercaptopurine therapy in adult acute lymphoblastic leukemia].
Hao QS; Wang Z; Fang QY; Gong XY; Liu KQ; Li Y; Wei H; Wang Y; Li QH; Wang M; Tian Z; Wang JX; Mi YC
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):911-916. PubMed ID: 35045652
[No Abstract] [Full Text] [Related]
16. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.
Tamm R; Mägi R; Tremmel R; Winter S; Mihailov E; Smid A; Möricke A; Klein K; Schrappe M; Stanulla M; Houlston R; Weinshilboum R; Mlinarič Raščan I; Metspalu A; Milani L; Schwab M; Schaeffeler E
Clin Pharmacol Ther; 2017 May; 101(5):684-695. PubMed ID: 27770449
[TBL] [Abstract][Full Text] [Related]
20. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
Stocco G; Yang W; Crews KR; Thierfelder WE; Decorti G; Londero M; Franca R; Rabusin M; Valsecchi MG; Pei D; Cheng C; Paugh SW; Ramsey LB; Diouf B; McCorkle JR; Jones TS; Pui CH; Relling MV; Evans WE
Hum Mol Genet; 2012 Nov; 21(21):4793-804. PubMed ID: 22846425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
